Comella, P., Massidda, B., Natale, D., Filippelli, G., Farris, A., Palmeri, S., et al. (2009). “Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)”. ??????? it.cilea.surplus.oa.citation.tipologie.CitationProceedings.prensentedAt ??????? Gastrointestinal Cancers Symposium.

“Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)”

PALMERI, Sergio;
2009-01-01

2009
Gastrointestinal Cancers Symposium
2009
1
Comella, P., Massidda, B., Natale, D., Filippelli, G., Farris, A., Palmeri, S., et al. (2009). “Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)”. ??????? it.cilea.surplus.oa.citation.tipologie.CitationProceedings.prensentedAt ??????? Gastrointestinal Cancers Symposium.
Proceedings (atti dei congressi)
Comella, P; Massidda, B; Natale, D; Filippelli, G; Farris, A; Palmeri, S; Condemi, G; Tafuto, S; Vessia, G; Barberis, G; Sandomenico, C
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/45336
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact